Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis

被引：41
作者：
Chen, Linyan [1 ,2 ,3 ]
Zhang, Yi [1 ,2 ,3 ]
Cheng, Yuan [1 ,2 ,3 ]
Zhang, Dan [1 ,2 ,3 ]
Zhu, Sha [1 ,2 ,3 ]
Ma, Xuelei [1 ,2 ]
机构：
[1] Sichuan Univ, State Key Lab Biotherapy, Dept Biotherapy, West China Hosp,Canc Ctr, Chengdu, Sichuan, Peoples R China
[2] Collaborat Innovat Ctr, Chengdu, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, West China Sch Med, Chengdu, Sichuan, Peoples R China
来源：
GENE | 2018年 / 679卷
关键词：
Circulating cell-free DNA; Prognosis; Pancreatic cancer; Meta-analysis; TUMOR DNA; KRAS MUTATIONS; BREAST-CANCER; PLASMA; MARKER; SERUM; SURVIVAL; GEMCITABINE; UTILITY; CA19-9;
D O I：
10.1016/j.gene.2018.09.029
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Because of the deep research about tumorigenesis mechanism, the cognition of cancer has been transferred to molecular level from morphology. Previous articles reported a potential connection between circulating cell-free DNA (cfDNA) and prognosis of pancreatic cancer. A total of 18 related articles including 1243 patients were enrolled to access the relationship between cfDNA and prognosis of pancreatic cancer. The hazard ratio (HR) was used to combine the univariate and multivariate results of included studies. Our result performed that the cfDNA had significant prognostic value in predicting OS (HR = 2.41, 95%CI: 1.93-3.02, I-2 = 60%) and PFS (HR = 2.47, 95,/oCI: 1.80-3.40, I-2 = 0%) in univariate analysis. The multivariate analyses about OS (HR = 2.57, 95%CI: 1.95-3.38, I-2 = 66%) and PFS (HR = 2.31, 95%CI: 1.47-3.64, I-2 = 0%) also showed significance. In conclusion, the cfDNA was a significant prognostic factor for OS and PFS in patients with pancreatic cancer. The mutation (Kras, ERBB2-exonl7 and KrasG12V), circulating tumor DNA (ctDNA) presence, hypermethylation and higher concentration of cfDNA were both associated with worse survival results in pancreatic cancer.
引用
收藏
页码：328 / 334
页数：7
相关论文
共 50 条
[1]   Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer [J].
Adamo, Patricia ;
Cowley, Caroline M. ;
Neal, Christopher P. ;
Mistry, Vilas ;
Page, Karen ;
Dennison, Ashley R. ;
Isherwood, John ;
Hastings, Robert ;
Luo, Jinli ;
Moore, David A. ;
Pringle, J. Howard ;
Martins, L. Miguel ;
Pritchard, Catrin ;
Manson, Margaret ;
Shaw, Jacqui A. .
ONCOTARGET, 2017, 8 (50) :87221-87233
[2]   Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue [J].
Ako, Soichiro ;
Nouso, Kazuhiro ;
Kinugasa, Hideaki ;
Dohi, Chihiro ;
Matushita, Hiroshi ;
Mizukawa, Sho ;
Muro, Shinichiro ;
Akimoto, Yutaka ;
Uchida, Daisuke ;
Tomoda, Takeshi ;
Matsumoto, Kazuyuki ;
Horiguchi, Shigeru ;
Tsutsumi, Koichiro ;
Kato, Hironari ;
Okada, Hiroyuki .
PANCREATOLOGY, 2017, 17 (02) :285-290
[3]  
[Anonymous], 2010, CANC FACTS FIG 2015
[4]  
[Anonymous], 2014, World Cancer Report
[5]   Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? [J].
Camps, C ;
Sirera, R ;
Bremnes, R ;
Blasco, A ;
Sancho, E ;
Bayo, P ;
Safont, MJ ;
Sánchez, JJ ;
Tarón, M ;
Rosell, R .
LUNG CANCER, 2005, 50 (03) :339-346
[6]   The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients [J].
Camps, Carlos ;
Jantus-Lewintre, Eloisa ;
Cabrera, Andrea ;
Blasco, Ana ;
Sanmartin, Elena ;
Gallach, Sandra ;
Caballero, Cristina ;
del Pozo, Nieves ;
Rosell, Rafael ;
Guijarro, Ricardo ;
Sirera, Rafael .
LUNG CANCER, 2011, 72 (03) :365-369
[7]   K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma:: Diagnostic utility and prognostic significance [J].
Castells, A ;
Puig, P ;
Móra, J ;
Boadas, J ;
Boix, L ;
Urgell, E ;
Solé, M ;
Capellà, G ;
Lluis, F ;
Fernández-Cruz, L ;
Navarro, S ;
Farré, A .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :578-584
[8]   K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer [J].
Chen, H. ;
Tu, H. ;
Meng, Z. Q. ;
Chen, Z. ;
Wang, P. ;
Liu, L. M. .
EJSO, 2010, 36 (07) :657-662
[9]   Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients [J].
Cheng, He ;
Liu, Chen ;
Jiang, Jiahao ;
Luo, Guopei ;
Lu, Yu ;
Jin, Kaizhou ;
Guo, Meng ;
Zhang, Zhenzhen ;
Xu, Jin ;
Liu, Liang ;
Ni, Quanxing ;
Yu, Xianjun .
INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (10) :2344-2350
[10]  
Dabizzi Emanuele, 2011, Cancers (Basel), V3, P494, DOI 10.3390/cancers3010494
12345